GCG and type 2 diabetes mellitus: Signal transduction occurs after GLP-1R agonists bind to GLP-1Rs, mirroring a GLP-1 bioactivity effect favourable for patients with T2D, where this incretin therapy lowers blood glucose levels by stimulating insulin secretion from β-cells.